TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca2+ influx
Jianpeng Chen(Southern Medical University), Rong Li(Nanfang Hospital), Yi Luan, Xiaohua Chen(Lanzhou University), Changxuan You(Southern Medical University), Rongcheng Luo(TCM-Intigrated Cancer Center of Southern Medical University)
Cited by 135
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients
|Biomedicine & Pharmacotherapy|2015|126
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
|Annals of Oncology|2013|120
MiR‐219‐5p inhibits hepatocellular carcinoma cell proliferation by targeting glypican‐3
|FEBS Letters|2012|102